698 related articles for article (PubMed ID: 18050251)
1. Persistence of abnormal bronchoalveolar lavage findings after cyclophosphamide treatment in scleroderma patients with interstitial lung disease.
Mittoo S; Wigley FM; Wise R; Xiao H; Hummers L
Arthritis Rheum; 2007 Dec; 56(12):4195-202. PubMed ID: 18050251
[TBL] [Abstract][Full Text] [Related]
2. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma alveolitis.
Colaci M; Sebastiani M; Giuggioli D; Manfredi A; Spagnolo P; Luppi F; Richeldi L; Ferri C
Scand J Rheumatol; 2010 Mar; 39(2):155-9. PubMed ID: 20059446
[TBL] [Abstract][Full Text] [Related]
3. Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression.
Goh NS; Veeraraghavan S; Desai SR; Cramer D; Hansell DM; Denton CP; Black CM; du Bois RM; Wells AU
Arthritis Rheum; 2007 Jun; 56(6):2005-12. PubMed ID: 17530640
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study.
Bérezné A; Ranque B; Valeyre D; Brauner M; Allanore Y; Launay D; Le Guern V; Kahn JE; Couderc LJ; Constans J; Cohen P; Mahr A; Pagnoux C; Hachulla E; Kahan A; Cabane J; Guillevin L; Mouthon L
J Rheumatol; 2008 Jun; 35(6):1064-72. PubMed ID: 18464307
[TBL] [Abstract][Full Text] [Related]
5. Cyclophosphamide versus placebo in scleroderma lung disease.
Tashkin DP; Elashoff R; Clements PJ; Goldin J; Roth MD; Furst DE; Arriola E; Silver R; Strange C; Bolster M; Seibold JR; Riley DJ; Hsu VM; Varga J; Schraufnagel DE; Theodore A; Simms R; Wise R; Wigley F; White B; Steen V; Read C; Mayes M; Parsley E; Mubarak K; Connolly MK; Golden J; Olman M; Fessler B; Rothfield N; Metersky M;
N Engl J Med; 2006 Jun; 354(25):2655-66. PubMed ID: 16790698
[TBL] [Abstract][Full Text] [Related]
6. High-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: a prospective open study.
Wanchu A; Suryanaryana BS; Sharma S; Sharma A; Bambery P
Int J Rheum Dis; 2009 Sep; 12(3):239-42. PubMed ID: 20374353
[TBL] [Abstract][Full Text] [Related]
7. Determinants of pulmonary function improvement in patients with scleroderma and interstitial lung disease.
Tzelepis GE; Plastiras SC; Karadimitrakis SP; Vlachoyiannopoulos PG
Clin Exp Rheumatol; 2007; 25(5):734-9. PubMed ID: 18078622
[TBL] [Abstract][Full Text] [Related]
8. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
Hoyles RK; Ellis RW; Wellsbury J; Lees B; Newlands P; Goh NS; Roberts C; Desai S; Herrick AL; McHugh NJ; Foley NM; Pearson SB; Emery P; Veale DJ; Denton CP; Wells AU; Black CM; du Bois RM
Arthritis Rheum; 2006 Dec; 54(12):3962-70. PubMed ID: 17133610
[TBL] [Abstract][Full Text] [Related]
9. [Correlation between bronchoalveolar lavage and lung function in patients with systemic sclerosis and rheumatoid arthritis].
Pejcić T; Stanković I; Rancić M; Djordjević I; Ristić L; Vojinović J
Srp Arh Celok Lek; 2005 Dec; 133 Suppl 2():129-33. PubMed ID: 16535997
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy of ab initio immunosuppressive therapy and steroid-sparing effect in interstitial lung disease associated with antisynthetase antibody syndrome].
Franzolini N; Quartuccio L; De Marchi G; De Vita S
Reumatismo; 2007; 59(3):202-8. PubMed ID: 17898879
[TBL] [Abstract][Full Text] [Related]
11. Cyclophosphamide reduces neutrophilic alveolitis in patients with scleroderma lung disease: a retrospective analysis of serial bronchoalveolar lavage investigations.
Kowal-Bielecka O; Kowal K; Rojewska J; Bodzenta-Lukaszyk A; Siergiejko Z; Sierakowska M; Sierakowski S
Ann Rheum Dis; 2005 Sep; 64(9):1343-6. PubMed ID: 16100339
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of patients with scleroderma interstitial lung disease treated with intravenous cyclophosphamide pulse therapy: a single-center experience.
Balbir-Gurman A; Yigla M; Guralnik L; Hardak E; Solomonov A; Rozin AP; Toledano K; Dagan A; Bishara R; Markovits D; Nahir MA; Braun-Moscovici Y
Isr Med Assoc J; 2015 Mar; 17(3):150-6. PubMed ID: 25946765
[TBL] [Abstract][Full Text] [Related]
13. Induced sputum in systemic sclerosis interstitial lung disease: comparison to healthy controls and bronchoalveolar lavage.
Damjanov N; Ostojic P; Kaloudi O; Alari S; Guiducci S; Stanflin N; Nestorovic B; Knezevic J; Camiciottoli G; Porta F; Pistolesi M; Ibba-Manneschi L; Conforti ML; Candelieri A; Matucci Cerinic M
Respiration; 2009; 78(1):56-62. PubMed ID: 18931474
[TBL] [Abstract][Full Text] [Related]
14. Interstitial lung disease associated with systemic sclerosis: what is the evidence for efficacy of cyclophosphamide?
Bérezné A; Valeyre D; Ranque B; Guillevin L; Mouthon L
Ann N Y Acad Sci; 2007 Sep; 1110():271-84. PubMed ID: 17911442
[TBL] [Abstract][Full Text] [Related]
15. A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease.
Várai G; Earle L; Jimenez SA; Steiner RM; Varga J
J Rheumatol; 1998 Jul; 25(7):1325-9. PubMed ID: 9676764
[TBL] [Abstract][Full Text] [Related]
16. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study.
Khanna D; Clements PJ; Furst DE; Chon Y; Elashoff R; Roth MD; Sterz MG; Chung J; FitzGerald JD; Seibold JR; Varga J; Theodore A; Wigley FM; Silver RM; Steen VD; Mayes MD; Connolly MK; Fessler BJ; Rothfield NF; Mubarak K; Molitor J; Tashkin DP;
Arthritis Rheum; 2005 Feb; 52(2):592-600. PubMed ID: 15692967
[TBL] [Abstract][Full Text] [Related]
17. Bronchoalveolar lavage fluid in scleroderma interstitial lung disease: technical aspects and clinical correlations: review of the literature.
Kowal-Bielecka O; Kowal K; Highland KB; Silver RM
Semin Arthritis Rheum; 2010 Aug; 40(1):73-88. PubMed ID: 19152959
[TBL] [Abstract][Full Text] [Related]
18. Bronchoalveolar lavage in systemic sclerosis with lung involvement: role and correlations with functional, radiological and scintigraphic parameters.
Volpinari S; La Corte R; Bighi S; Ravenna F; Prandini N; Lo Monaco A; Trotta F
Rheumatol Int; 2011 Sep; 31(9):1183-8. PubMed ID: 20352228
[TBL] [Abstract][Full Text] [Related]
19. Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis.
Giacomelli R; Valentini G; Salsano F; Cipriani P; Sambo P; Conforti ML; Fulminis A; De Luca A; Farina G; Candela M; Generini S; De Francisci A; Tirri E; Proietti M; Bombardieri S; Gabrielli A; Tonietti G; Cerinic MM
J Rheumatol; 2002 Apr; 29(4):731-6. PubMed ID: 11950014
[TBL] [Abstract][Full Text] [Related]
20. Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study.
Khanna D; Yan X; Tashkin DP; Furst DE; Elashoff R; Roth MD; Silver R; Strange C; Bolster M; Seibold JR; Riley DJ; Hsu VM; Varga J; Schraufnagel DE; Theodore A; Simms R; Wise R; Wigley F; White B; Steen V; Read C; Mayes M; Parsley E; Mubarak K; Connolly MK; Golden J; Olman M; Fessler B; Rothfield N; Metersky M; Clements PJ;
Arthritis Rheum; 2007 May; 56(5):1676-84. PubMed ID: 17469162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]